Stunningly elevated age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines (Pfizer & Moderna); Le Vu et al.; elevated risks of myocarditis & pericarditis

by Paul Alexander

increased risks of myocarditis & pericarditis during first week following vaccination, & particularly after the second dose, Moderna (yet both Pfizer & Moderna), persons aged 18 to 24, males & females

Nationwide hospital discharge and vaccine data, we analyzed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. matched those cases to 16,120 and 16,130 control subjects, respectively.

Researchers found significant elevated risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the Pfizer and 30 (95% CI, 21 to 43) for the Moderna (mRNA-1273) vaccine. They found the largest associations for myocarditis following Moderna vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.’